In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

Ziresovir earns global recognition, boosting hope for young RSV patients and strengthening ArkBio’s innovative pipeline.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

The Royal Australian College of GPs (RACGP) has welcomed a new Victorian Government program to provide free respiratory syncytial virus (RSV) vaccines ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

OLDER adults are being encouraged by NHS Ayrshire and Arran to take up a potentially life-saving new vaccine. The health board is urging people to get vaccinated against Respiratory Syncytial Virus ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...